Ovarian cancer is the most lethal gynecological malignancy due to the silent nature on its early onset and the rapid acquisition of drug resistance. Histologically heterogeneous, it includes several subtypes with different mutational landscapes, hampering the development of effective targeted therapies. Non-coding RNAs are emerging as potential new therapeutic targets in cancer. To search for a microRNA signature related to ovarian carcinomas and study its potential as effective targeted therapy, we examined the expression of 768 miRNA in a large collection of tumor samples and found miR-654-5p to be infraexpressed in ovarian serous carcinomas, the most common and aggressive type. Restoration of miR-654-5p levels reduced tumor cell viability in vitro and in vivo and impaired sphere formation capacity and viability of ovarian cancer patient-derived ascitic cells ex vivo. CDCP1 and PLAGL2 oncogenes were found to be the most relevant direct miR-654-5p targets and both genes convey in a molecular signature associated with key cancer pathways relevant to ovarian tumorigenesis, such as MYC, WNT and AKT pathways. Together, we unveiled the tumor suppressor function of miR-654-5p, suggesting that its restoration or co-targeting of CDCP1 and PLAGL2 may be an effective therapeutic approach for ovarian cancer.
Introduction
Ovarian cancer (OC) is the most lethal gynecological malignancy [1] and includes different subtypes, being highgrade serous carcinoma (HGSC) the most common and aggressive subtype [2] . Despite the efforts devoted to improve early diagnosis [3, 4] , the disease still remains largely incurable, in part due to the presence of ascites in advanced stages [5] . Over the past 50 years, the first-line chemotherapy for OC, composed mainly of platinum and taxane derivatives [6] , has neither varied nor resulted into a significant improved overall survival [6] . Recently, targeted therapies against PI3K, MEK, EGFR and key regulators of the cell cycle, among others [7] are on the horizon of new treatments for OC. Still under the regimen of recurrent OC, some improvements have been achieved with the introduction in the therapeutic pipeline of anti-angiogenic agents [7] , and PARP inhibitors for BRCA mutation carriers [8] and patients with a "BRCAness" phenotype [9] . However, and due to the heterogeneity of the disease, a deeper molecular understanding of the tumor biology is needed to generate novel and efficient therapies. Recent evidence suggests that modulation of microRNA (miRNA) levels, a type of small (∼18-22 nt) non-coding RNAs, can be a novel therapeutic approach for cancer and other diseases [10] thanks to the ability of a particular miRNA to target multiple genes that might be altered in specific disease conditions. A considerable number of preclinical studies involving miRNA therapeutics have been conducted over the last years [11] . Several miRNA have been shown to be downregulated in ovarian tumors, associated to shorter or poorer overall survival and related to better response to chemotherapy [12] [13] [14] [15] [16] . However, only few of them have moved into clinical trials [10] , such as the first phase I study in humans that has been completed in 2017 using miR-34a for the treatment of advanced solid tumors [17] .
The heterogeneity of miRNA-detecting platforms and patient cohorts hamper the interpretation of the results across studies and the implementation of miRNAs as therapeutic tools in OC [12] . Here, we provide an extensive study of miRNA expression in more than 200 tissue samples, and the use of clinically representative models that better recapitulate the human disease. We have found that the restoration of miR-654 expression levels significantly inhibited cell proliferation and induced apoptosis in vitro, in vivo and in ex vivo patient derived-ascitic cell models. Further investigation into its mechanism of action showed that miR-654 altered the expression of CDCP1 and PLAGL2, thereby impacting on the oncogenic function of MYC, AKT and Wnt pathway, opening novel possibilities for the treatment of OC.
Results

MmiR-654 is downregulated in ovarian tumors
In an attempt to identify new targets for OC therapy, we analyzed miRNA expression levels in advanced-stage OC patients, under the arguably hypothesis that deregulated miRNA in shorter living patients could potentially be involved in the disease progression and serve as novel therapeutic targets. Patients were classified into two groups (n = 107) according to an overall survival of less than 3 or more than 8 years (short-and long-term survival; SSV and LSV, respectively; Supplementary Table 1a) . We initially used a cohort of 27 OC FFPE primary tumors (Supplementary Fig. 1a ) and profiled miRNA levels. Thirty-two miRNA were found differentially expressed between both groups (Fig. 1a, Supplementary Data S1) . Unsupervised hierarchical clustering analysis showed that the majority of patients clustered according to their survival group (Fig. 1a) . Next, we used an independent multicenter cohort of 80 FFPE samples ( Supplementary Fig. 1a ) to validate the identified miRNA (Fig. 1a , Supplementary Data S1), and found 4 miRNA, namely miR-654, miR-554, miR-409-3p and miR-127-3p that displayed higher levels in tumors from SSV compared to LSV patients with p-value < 0.05 and fold change > 1.5 ( Supplementary Fig. 1b, c) .
We then modulated the expression of the 4-validated miRNA in multiple OC cell lines and found that miR-654 overexpression decreased cell proliferation in all lines tested (Fig. 1b) , while its inhibition increased proliferation in 3 of the 4 OC cell lines ( Supplementary Fig. 1d ). Despite this was in apparent contradiction with the observation that miR-654 levels were higher in SSV patients, the consequences of its modulation in vitro suggests that miR-654 presumably acts as a tumor suppressor in OC. Supporting this hypothesis we found lower levels of miR-654 in tumors compared to benign ovarian tissues (Fig. 1c) (n = 84, Supplementary Table 1b) , which were further decreased in the HGSC histology, the most aggressive type of OC (Fig.  1d) . A small cohort from the initial screening, with extended clinical follow up, revealed that the difference between SSV vs. LSV samples, albeit significant in agreement to our initial observation, was within the lower expression range that tumoral samples display for miR-654 compared to benign samples (Fig. 1c) . Kaplan-Meier survival curves from HGSC tumors ( Supplementary Fig. 1c ) reflected that high miR-654 expression related to poorer survival (Supplementary Fig. 1e ), suggesting a prognostic role for miR-654 levels within tumors. In addition, no differences were found when tumors where grouped as early-or advancedstage OC ( Supplementary Fig. 1f ), or between paired tumor and metastases samples from HGSC patients (Supplementary Fig. 1g ) (Supplementary Table 1c ), supporting the hypothesis that the reduction on miR-654 levels may be more related to the initiation of the disease, and points towards a tumor suppressor role for miR-654.
MiR-654 promoter region is hypermethylated in OC cell lines and tissues
MiR-654 is located in Chromosome 14, within the q32.31 chromosomal region, a region frequently altered in cancer [18] [19] [20] , including OC [13] . Here, we found hypermethylation in the CpG islands of 79 and 89% of tumors and cell lines evaluated, respectively, with a β-value ≥ 0.5 (Fig. 1e) . Accordingly, the levels of miR-654 significantly raised upon DNA methyltransferase inhibition in OAW28 cells and the same tendency was observed for A2780 cells (Fig. 1f) (two of the cell lines that expressed low miR-654 levels, Supplementary Fig. 1h ; and high levels of hypermethylation). This was accompanied by increased expression of MEG3, GBGT1 and MAGE-A3 positive control genes [21] [22] [23] (Supplementary Fig. 1i ). Together, this suggests that hypermethylation could be responsible in part for the low miR-654 levels found in OC, despite other mechanisms may be regulating miR-654 expression in OC.
Overexpression of miR-654 reduces cell viability and sensitizes cells to paclitaxel in vitro
The effects of miR-654 ectopic expression were analyzed and a 50% reduction in cell proliferation was observed in SKOV3 and A2780 cells in a miR-654 overexpression time-course (Fig. 2a, Supplementary Fig. 2a, b) . Cell death was analyzed in 4 OC cell lines finding the number of apoptotic cells significantly increased upon miR-654 transfection compared to miR-Control-cells (Fig. 2b, c) , which was confirmed by the cleavage of Caspase-3 and its substrate PARP-1 (Fig. 2d) . We found that miR-654 did not induce cell death in the presence of the caspase-inhibitor Q/ VD/OPH, thereby indicating that miR-654-induced cell death is caspase-dependent ( Supplementary Fig. 2c ). Furthermore, cell cycle profile analysis showed a subG1 peak at 96 h post-miR-654 transfection ( Supplementary Fig. 2d ), consistent with the increased cell death observed, and a slight increase in the percentage of cells in G1 (Supplementary Fig. 2e ), suggesting that miR-654 overexpression caused an initial cell cycle delay that may add to the reduced proliferation observed. To test whether miR-654 sensitize cells to paclitaxel, SKOV3 and A2780 cells were treated with paclitaxel at different doses and transfected with miR-654, showing a synergistic effect in reducing cell viability (Fig. 2e, Supplementary Fig. 2f, g ), and suggesting that the combination of miR-654 and paclitaxel may be a suitable therapy for OC.
MiR-654 expression reduces the viability of OC patient-derived ascitic cells
Tumor ascites, which survive in anchorage-independent conditions growing as spheroids and drive OC progression at later stages [24] , are a major source of disease recurrence. Patient-derived ascitic cells were grown ex vivo to evaluate the potential therapeutic role of miR-654 in advanced disease stages, finding that miR-654 overexpression significantly reduced the number, size and viability of spheroids ( Fig. 2f-h) , and increased spheroid caspase-dependent apoptosis (Fig. 2i) . Altogether, this mirrored the previous results observed in OC cell lines and empowered in addition patient-derived ascites as ex vivo models to evaluate novel therapies for advanced-stage OC patients.
MmiR-654 overexpression impairs tumor growth in vivo
To recapitulate in vivo the results obtained in vitro, 2 × 10 6 miR-Control and miR-654 transfected SKOV3 cells were injected in the flank of nude mice (n = 12/group) and monitored as shown in Fig. 3a . MiRr-654 overexpression was confirmed before cell implantation, at 5 days postinjection and at the end of the experiment (Fig. 3b-d) . Eight days post-injection, all miR-Control mice developed tumors whereas only 40% of miR-654 mice did so (Fig. 3e) . Significant differences in tumor volume were visible at 11 days post-injection and maintained through the experiment (Fig.  3f ). Mice were sacrificed at day 25 and tumors were weighted and imaged, finding smaller tumors in the miR-654 group (Fig. 3g, h ). Importantly, miR-654 levels inversely correlated with tumor volume (r = −0.95, Fig. 3i ) and weight (r = −0.8619, Supplementary Fig. 3a ) and both positively correlated between each other, confirming the accuracy of the measures ( Supplementary Fig. 3b ).
Moreover, reduced cellularity, larger areas of collagen deposition and decreased percentage of Ki67 positive cells were visible in mice sacrificed at day 5 post-injection (Fig.  3j, k) and remained until the end of the experiment (Supplementary Fig. 3c) ; phenotype commonly observed after chemotherapy, where the extracellular matrix fuels the empty spaces left by death cells [25] . Of note, some tumors from the miR-Control group invaded the dermis, while none of the miR-654 mice group did so ( Supplementary Fig. 3d ). Altogether, miR-654 reduced tumor growth in vivo, inducing regressive changes at initial steps after the engraftment determining the tumor fate.
MiR-654 targets multiple genes involved in apoptosis, cell proliferation and survival pathways
To understand the molecular mechanisms regulated by miR-654, we followed the workflow shown in Fig. 4a . First, a whole transcriptome 3′UTR search for miR-654 binding sites was conducted using the in silico platform miRWalk2.0 [26] that revealed a list of 2302 putative target genes. Of those, 46 were predicted by at least 5 different algorithms (Supplementary Table 1l ) and 14 were finally selected according to previously described functions related to the observed miR-654 phenotypes. Upon miR-654 overexpression 5 of those 14 candidates suffered a reduction in the mRNA levels in SKOV3 and A2780 cells with more than 50% reduction in at least one of them (Fig. 4b , red asterisks) ( Supplementary Fig. 4a ). At protein level, HAX1, RAB1B and PLAGL2 appeared decreased in both cell lines at different time points post-transfection, while CDCP1 and PBX3 protein levels did so only in SKOV3 Fig. 1 Decreased miR-654 expression and hypermethylation of its locus are found in OC. a Unsupervised hierarchical clustering of the 32 differentially expressed miRNA (FDR < 0.05) found in the discovery phase (n = 25, as two patients were outliers; see also Supplementary Methods), in SSV compared to LSV patients. b Evaluation of the proliferation effect in miRNA mimic-transfected indicated OC cells 96 h post-transfection. Graph represents the mean ± SEM of three independent experiments (n = 6/condition). c Relative miR-654 expression levels in benign lesions (n = 29) compared to ovarian tumors (n = 55); and in a cohort of LSV vs. SSV tumors (n = 8) randomly selected fro (a). d Relative miR-654 expression levels in ovarian tumors according to their histology. e Methylation analysis of the 13 CpG sites of the miR-654 locus in OC cell lines (top) and tumors (bottom). f MiR-654 levels upon treatment with 1 μM of 5-AZA-2'-deoxycytidine at the indicated times. Graph represents the mean ± SEM of 2 independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. p values were calculated using unpaired student's t-test for (b) and (f), and non-parametric MannWhitney tests for (c) and (d). See Supplementary Methods for statistics of (A) cells (Fig. 4c) , possibly due to different protein stability between both cell lines. Furthermore, luciferase-reporter assays upon miR-654 overexpression showed a significant reduction in luciferase activity for all 3′UTR engineered regions and this was significantly rescued when seed sequences in the 3′UTR regions of all targets were mutated ( Fig. 4d, Supplementary Table 1k ), indicating a direct modulation of these genes by miR-654.
CDCP1 and PLAGL2 knockdown phenocopies miR-654 overexpression in vitro
To gain insights into the molecular mechanisms driven by miR-654 through its targets, HAX1, RAB1B, PBX3, CDCP1 or PLAGL2 were silenced in SKOV3 cells (Supplementary Fig. 4b ). CDCP1 and PLAGL2 silencing best recapitulated the effects of miR-654 overexpression, reducing proliferation (Fig. 4e ) and increasing the percentage of apoptotic cells comparably to miR-654 overexpression (Fig.  4f, g ). In addition, overexpression of miR-654 in the ex vivo patient-derived ascitic cell models resulted in diminished protein levels of CDCP1, PLAGL2 and RAB1B (Fig. 4h) , thereby suggesting that these 3 genes could be mediators of the miR-654 effects in this context. Interestingly, we found higher CDCP1 and PLAGL2 levels in HGSC OC samples compared to benign lesions (Fig. 4i ), while RAB1B levels were similar between groups ( Supplementary Fig. 4c ). We found that CDCP1 or PLAGL2 and miR-654 levels inversely correlated (although did not reach statistically significance for PLAGL2 and miR-654) ( Supplementary Fig.  4d ). This suggests that CDCP1 correlates better with miR-654 levels and the clinical parameters, indicating a close relation of miR-654/CDCP1 with OC progression. Instead, the lack of significant correlation between PLAGL2 and miR-654 in individual patients might indicate a more complex regulation of this target. Together, these results support the clinical relevance of targeting CDCP1 and PLAGL2 by miR-654 in OC.
MiR-654-CDCP1/PLAGL2 converge on the MYC, AKT and Wnt gene sets
For the abovementioned reasons, we focused on understanding CDCP1 and PLAGL2 signaling networks regulated by miR-654 hereafter. To this end, a whole transcriptome analysis was performed after silencing CDCP1 or PLAGL2 in SKOV3 cells (Fig. 5a ). Principal component analysis (PCA) segregated siControl vs. siCDCP1 or siPLAGL2 samples indicating a consistent transcriptional impact after both gene depletions (Fig. 5b) , and a high number of differential expressed genes (Fig. 5c , FDR < 0.25 and fold change > ± 1.5). Interestingly, 70 and 60 genes were commonly down and upregulated, respectively, by CDCP1 and PLAGL2 silencing (Fig. 5d) , denoting that part of the transcriptional changes partially overlapped between both genes. Functional annotation using DAVID bioinformatic tools showed that CDCP1 and PLAGL2 depletions significantly impacted on genes associated to canonical KEGG pathways in cancer (Fig. 5e , >10 genes and p < 0.05), and to GO terms related to cell proliferation and apoptotic processes, among others (Supplementary Fig. 5a ). Furthermore, gene set enrichment analysis (GSEA) was performed using major gene set collections, resulting in a vast number of significantly enriched gene sets for both gene conditions ( Supplementary Fig. 5b ). Then, gene sets related to apoptosis, HIF-1, focal adhesion, Wnt, MYC, actin cytoskeleton, MAPK, AKT, FoxO, Proteoglycan in cancer, and angiogenesis were used for a second GSEA, according to the most represented functions found in the DAVID analyses and the first GSEA. Noticeably, several enriched gene sets related to MYC, AKT and Wnt pathway were commonly altered by CDCP1 and PLAGL2 knockdown, among others ( Fig. 5f -h, Supplementary Fig. 5c , and Supplementary Methods). MYC levels appeared downregulated by both CDCP1 and PLAGL2 depletions (Fig. 5h, top left) , as well as several regulators of the Wnt pathway such SMURF2 and DKK1 (Fig. 5h, top  right) . Additionally, several cyclin-dependent kinases (CDKs) such as CDK2 and CDK4 diminished upon PLAGL2 depletion (Fig. 5h, bottom right) , as well as the levels of AKT2 and retinoblastoma (RB) (Fig. 5h , bottom right), thus suggesting that reduction of the expression of these genes might contribute to the effects of miR-654 overexpression on cell survival. In agreement with the hypothesis that part of the miR-654 phenotypic effects occur through the reduction of CDCP1 and PLAGL2 levels in OC, we found diminished protein levels of MYC, p-AKT, CDK2/4, RB, p-RB and β-catenin (β-cat, gene symbol CTNNB1), and increased levels of p27 (also CDKN1B) upon overexpression of miR-654 in SKOV3 cells (Fig. 5i) , confirming the expected molecular events that accompany a slower cell cycle progression and a decreased cell survival.
We also sought to explore whether these pathways were modulated by miR-654 in the patient-derived ascitic cell models and, concurring with our previous results, the protein levels of MYC, p-AKT, CDK2/4 and β-cat were diminished upon miR-654 overexpression in patient-derived ascites (Fig. 5j) . Altogether, these results suggested that the tumor suppressor functions of miR-654 are mediated, in part, by the modulation of its direct targets, CDCP1 and PLAGL2, which in turn modulate key pathways in OC, such as MYC, AKT and Wnt pathways (Fig. 6 ).
Discussion
The clinical management of OC remains a challenge due to the fact that high-grade histologies generally become resistant to standard therapies [3] . Moreover, the ability to translate the increasing knowledge on the genetic alterations into more effective treatments for OC had, so far, limited clinical impact in part due to the heterogeneity of the disease. In the present study, we found 4 miRNA whose levels were higher in tumors from SSV OC patients, suggesting at first glance an oncogenic role for them. However, the restoration of miR-127-3p and miR-654 reduced cell proliferation, evoking tumor suppressive rather than oncogenic properties. A plausible explanation is that SSV tumors could be more infiltrated with certain cell types from the immune system that have been associated to poorer prognosis in OC [27] , which may contribute to the increased levels of miR-654 found in SSV compared to LSV tumors (our preliminary results). In agreement with the previous phenotype, we found higher miR-654 levels in normal samples than in OC tumors, which was also seen for miR-127-3p [28] , suggesting that their loss may contribute to the initiation of OC.
In accordance with the in vitro results, we proved for the first time that the ectopic expression of miR-654 reduced tumor growth in vivo and reduced viability of patientderived ascites grown ex vivo. Importantly, this is the first report that tested the effect of modulating a tumor suppressor miRNA on the sphere forming capacity and viability of OC patient-derived ascites. This model is not without limitations, as their use is limited to 4-6 passages [29] , but our results clearly suggest that the tumor-suppressive effects of miR-654 could be of clinical relevance. Nonetheless, other hits presumably accompany miR-654 loss in OC cell transformation, as inhibition of miR-654 in non-tumoral immortalized ovarian surface epithelial (IOSE) cells per se, does not impair the cell death by contact inhibition typically observed in these cells (not shown).
MiR-654 was firstly identified and annotated by Cummins JM et al. [30] in 2006, it is located in the 14q32 chromosomal region, and recently found downregulated in classic Hodgkin lymphoma [31] and breast cancer [32] . Here, we found that the 14q32 region is hypermethylated in human OC tissues and cell lines, and an increased expression of miR-654 was obtained upon DNA methyltransferase inhibition in vitro, suggesting that epigenetic silencing could be one of the possible mechanisms of miR-654 regulation. Concurring with this observation, the DLK1-MEG3 (Dlk1-Gtl2) cluster, which contains miR-654 in humans [33] , has been found epigenetically downregulated in OC through hypermethylation [13] .
To date, little is known about the downstream miR-654-dependent signaling, and EPSTI1 for breast [32] and AR for prostate [34] cancer were the only 2 direct targets identified thus far. In this study, we found HAX1, RAB1B, PBX3, CDCP1 and PLAGL2 to be direct miR-654 targets, and their silencing revealed that the miR-654-related phenotype in OC is primarily caused by direct targeting of CDCP1 and PLAGL2 oncogenes. Furthermore, CDCP1 and PLAGL2 levels were found to be increased in ovarian tumors compared to normal samples, which has also been seen in leukemia [35] for PLAGL2, and in other malignancies including OC [36, 37] for CDCP1, supporting their role in OC progression and turning them into attractive therapeutic targets.
Our transcriptomic analysis after CDCP1 and PLAGL2 depletion defined both genes as master regulators of MYC, AKT and Wnt pathway in OC cells, and several of the canonical genes altered at the transcriptome level were confirmed at protein level in OC cell and primary patientderived ascites. CDCP1 (CUB domain-containing protein 1) is a type I transmembrane glycoprotein, that activates cell survival pathways in OC to mediate spheroid formation and chemoresistance through the activation of p the AKT pathway [36, 37] . PLAGL2 belongs to the PLAG family of zing finger proteins [38] and acts as an oncogene by enhancing anchorage independent growth and inducing . **p < 0.01; ***p < 0.001; ****p < 0.0001. p values were calculated using unpaired student's t-test for (d), (e), (f), (g) tumors in mice [38] , in part through its downstream effector p-AKT [39] . Here, we found reduced AKT2 mRNA levels by PLAGL2 inhibition, which together with the reduced p-AKT levels observed upon miR-654 overexpression, suggest a possible contribution of CDCP1 and PLAGL2 to the regulation of AKT pathway through miR-654 signaling.
A striking decrease in p-RB was also observed upon miR-654 expression, possibly caused by the reduced p-AKT and CDK2/4 levels observed. In addition, 2 CDK regulatory proteins, CKS1B and p27, were found under and overexpressed, respectively, upon both CDCP1 and PLAGL2 inhibition, suggesting that cell cycle progression and survival was diminished in OC cells in part through defective CDKs function.
Importantly, this is the first report that relates CDCP1 and PLAGL2 with MYC, a master regulator of cancer cells [40] . MYC has been found to be mutated and amplified in HGSC [3, 16] and a good candidate for targeting platinum-resistant OC [41] , thereby suggesting that these patients would likely benefit of a miR-654-based therapy. Furthermore, several genes related to the Wnt pathway were found to be altered after CDCP1 and PLAGL2 depletion in OC cells, and reduced total β-cat protein levels were observed upon miR-654 overexpression in OC cells and primary ascites confirming the modulation of the Wnt pathway by miR-654. Whereas PLAGL2 has been shown to activate Wnt signaling in glioblastoma and colon cancer [42, 43] thereby resulting in an accumulation of total β-cat levels, CDCP1 had never been previously related to the Wnt pathway, which further supports the use of miR-654 as a potent Wnt-like inhibitor, through targeting CDCP1/PLAGL2.
In summary, miRNA-654 acts transversally against multiple pathways, including MYC, AKT and Wnt signaling in OC, reducing cell proliferation and promoting cell death (Fig. 6) . We found it downregulated in ovarian tumors, together with elevated levels of its direct targets CDCP1 and PLAGL2, which might contribute on boosting OC cells tumorigenicity. In summary, these results pinpoint that miR-654 restoration may be an effective strategy for the treatment of OC in combination with the current therapies. Table 1c ). All patients gave their written informed consent, and fresh tissues were collected conforming to the Institutional Review Board (IRB) (PRAMI3082015).
Materials and methods
Human samples
Cell culture
Commercial cell lines, SKOV3, OAW42, 59 M, OAW28, OVCAR4, TOV112, OV90, A2780, A2780cis, BIN67, IGROV1, IOSE-503, IOSE-385 and HEK293T were cultured with indicated culture media (Supplementary Table 1d ). Cells were regularly tested for mycoplasma contamination and authenticated by short tandem repeat profiling.
For patient-derived ascites primary cultures, cells were obtained from malignant ascitic fluid collected at the time of the surgery under the IRB approval, (Supplementary Table  1e ). Ascitic primary cultures were established following procedures previously described [29] . Immediately after surgery, the ascitic fluid was mixed (1:1) with Mix medium (Supplementary Table 1e ). After 1 week, medium was replaced to remove any remaining blood cells and adherent cells were grown until 4-6 passages. All cells were maintained at 37°C in a saturated atmosphere of 95% air and 5% CO 2 .
Human miRNA microarray Table 1a) were used for the discovery phase. Total RNA was used for the reverse Table 1a) , by using Custom TaqMan® Array MicroRNA Cards following the manufacture instructions.
RTqPCR
For miRNA analyses, 25 ng of total RNA was used for RT of each individual miRNA, by using specific TaqMan probes (Supplementary Table 1f ). Hsa-miR-572 was used as endogenous control. For mRNA analyses, 1 μg of total RNA was used for RT using SuperScript III enzyme (Invitrogen). Power SybrGreen Master MIX (Cat# 4367659) was used to analyze mRNA levels by the corresponding designed primers (Supplementary Table 1g ). GAPDH was used as endogenous control. Human samples were randomized for RNA extractions, RT reactions and RTqPCR analyses in all cases. Relative quantification of gene expression was performed with the 2 −ΔΔCt method [44] .
DNA methylation microarray
DNA methylation data was obtained from Illumina Infinium Human Methylation450 BeadChip arrays, and was downloaded from the TCGA portal [16] , GSE81224 dataset [45] , and the Cancer Epigenetics and Biology Program (PEBC) dataset (unpublished) for OC primary tumors (n = 35); and from the GSE68379 dataset [46] for OC cell lines (n = 43). Briefly, the GenomeStudio 2010.3, Methylation Module 1.8.5 was used as previously described [47] to calculate the methylation β-values of the 13 CpG sites of the miR-654 chromosomal region 14q32.1. The percentage of samples being hypermethylated was obtained by the average β-value of the 13 CpG sites.
DNA demethylating assay
OAW28 and A2780 cells were treated with DMSO or the DNA methyltransferase inhibitor 5'AZA-2'desoxycytidine (Sigma). At the indicated time points, cells were used for miR-654 evaluation. MEG3 (Chr.14), GBGT1 (Chr.9) and MAGE-A3 (Chr.X) genes were used as positive control.
Cell proliferation assay
Cells were reversely transfected with 25 nM of miRIDIAN miRNA mimic Negative Control, miRNA mimics or antagomiRs (Supplementary Table 1h ), or with 50 nM of the indicated siRNAs (Supplementary Table 1i ) using Lipofectamine® 2000 and seeded at 3·10 3 -10·10 3 in 96-well plates (n = 6/condition). At the indicated time points, cells were fixed with 4% formaldehyde, stained with 0.5% crystal violet, dissolved with 15% acetic acid and measured at 590 nm.
Protein extraction and western blot
Cells were harvested in RIPA buffer (Tris HCl 1.5 M pH = 8.8, NaCl 5 M, Triton X-100, EDTA 500 mM) with protease and phosphatase cocktail inhibitors (1183170001, P5726, P0044, Sigma). Lysis was done on ice for 1 h with 30 sec vortex/15 min. Proteins (20-80 ug) were resolved on 8-15% tris-glycine PAGE or pre-cast electrophoresis gels (Thermo Fisher), and transferred onto PVDF membranes, which were blocked for 1 h with 5% non-fat milk (Panreac) or 5% BSA (Sigma) and probed overnight at 4°C with the indicated antibodies (Supplementary Table 1j ). After 1 h incubation with horseradish peroxidase-conjugated secondary antibodies signal was acquired with Immobilon Western (Millipore) or ECL (GE Healthcare). 
Cell death assay
3D cultures from patient-derived ascitic cell
For sphere forming capacity, primary cultured ascitic cells were reverse transfected with Lipofectamine 2000® and Negative Control or miR-654 mimic (25 nM) and seeded at 15 × 10 3 in non-adherent 24-well plates (coated with 0.5% agar in non-supplemented medium), in serum-free medium (1:1-MCDB105:M199, Biological Industries) supplemented with 1X B27 (Invitrogen), 2 mM L-glutamine, and 20 ng/ mL EGF and FGF (ProSpec-Tany Technogene Ltd). At The high levels of hypermethylation could partly explain the low miR-654 levels found in found in OC tumors and cells lines, which accompanied by the enhanced CDCP1 and PLAGL2 levels might contribute to boost the tumorigenicity of OC cells. Furthermore, PLAGL2 and CDCP1 oncogenes appeared as relevant direct targets of miR-654 in OC since they mediate at least part of the miR-654 function in the studied models. In addition, CDCP1 and PLAGL2 impact on key cell regulators (red or green for genes found over or underexpressed upon CDPC1 and/or PLAG2 depletion and miR-654 overexpression), such as AKT, MYC and Wnt signaling pathways. Therefore, we show that overexpression of miRNA-654 reduces cell proliferation, induces apoptosis and sensitizes OC cells to paclitaxel addition. Together, our results suggest that restoration of miRNA-654 levels and/or co-targeting of PLAGL2 and CDCP1 oncogenes may be an efficient strategy for OC treatment in combination with the current therapies 96 h, spheres were collected for protein extraction, MTS assay and for scoring. For MTS assays, tumor spheres were washed with PBS 1 × , and disaggregated with 0.5 mL 1X StemPro® Accutase® (ThermoFisher). PMS:MTS (1:20) mixture was added 1:10 to each well containing 100 μL of disaggregated cells, and measured at 2-5 h.
Luciferase reporter assays
DNA fragments containing the miR-654 binding sites for each 3′UTR region (and their corresponding 3′UTR mutated regions) of HAX1, CDCP1, PBX3, PLAGL2 and RAB1B genes were synthesized (GeneArt TM String TM , ThermoFisher), amplified into the pCR TM II-Blunt-TOPO® vector (Invitrogen), and cloned into the psiCHECK TM -2 vector by using XhoI and NotI restriction sites (Supplementary Table  1k ). 3'UTR luciferase reporter assays were performed as previously described [49] . Briefly, HEK293T cells were seeded at 2 × 10 4 cells/p96-well plates and co-transfected with 50 ng of each psiCHECK TM -2-3′UTR vector and 25 nM of miR-654 mimic or Negative Control. Luciferase assays were performed after 24 h using the Dual-Glo® Luciferase Assay System (Promega) and renilla was normalized to the firefly luciferase activity.
Mouse xenograft
All procedures were carried under the approval of the Institutional Animal Care at VHIR (protocol number 85/ 12). 2 × 10 6 cells of SKOV3 explanted cells transfected with Negative Control and miR-654 mimics (25 nM) were injected in 8-week-old female NMRI-nude mice (Janvier, n = 12/group) in 300 μL of PBS 1X and Matrigel (1:1). Tumor volume was measured every 2-3 days using an electronic caliper, and at day 25 mice were sacrificed and tumors were removed and weighed. Each tumor was used for H&E and Ki67 staining and for RNA extraction.
Human mRNA microarray analyses SKOV3 cells transfected with siR-Control, siCDCP1 or siPLAGL2 (n = 3) were used in the microarray analysis. RNA concentration and quality were measured by Nanodrop and RNA Nano Chip Bioanalyzer (Agilent Technologies), and efficiency of CDCP1 and PLAGL2 depletion was measured by RTqPCR. Human Clariom TM S assay (Affymetrix) was used to analyze whole-transcriptome expression profiling, which detects more than 20,000 well-annotated genes. The High Technology Unit (UAT) at VHIR performed all the steps after RNA extraction, including the first and second strand cDNA production, biotinylation, hybridization, labeling and scanning of the chips. Microarray raw data is publicly available at the GEOarchive repository GSE113115.
Statistics
Sample size was chosen to ensure adequate statistical power, according to the availability of the samples at the VHUH and the prevalence of the disease. Unless otherwise indicated, mean ± SEM values are the average of three independent experiments. Statistical significance was determined by unpaired Student's t-test, assuming similar variances (GraphPad Prism Software, La Jolla, CA, USA). *p < 0.05; **p < 0.01; ***p < 0.001 and ****p < 0.0001. Identification of possible outliers was performed in all human data (ROUT method), the normal distribution of the data was verified (Shapiro-Wilk and Kolmogorov tests) and, accordingly, non-parametric Mann-Whitney test was used for comparisons between groups when analyzing human ovarian tissues. Compute correlations between pairs of data were performed by parametric Pearson and non-parametric Spearman correlation analyses. Unitat d'Alta Tecnologia (UAT) at VHIR. We thank all our lab members for support and helpful discussions. This work was sup Author contributions BM and AS conceived and designed the study with help of AP and MFS. BM performed the miRNA and mRNA microarray analyses, and CJ carried out the mRNA microarray statistics and bioinformatics. BM and AP carried out all experiments and data analyses with the help of LS and MB. AM and GT provided technical support. ME and SM performed the DNA methylation analyses. JC analyzed and interpreted the IHC. JLS, APB, and AGM coordinated samples collection at HUVH and XMG, GM, FA, JP, and JAL provided with OC samples for the multicenter study. JR and MR initiated the miRNA screening. BM and AS wrote the manuscript with input from all other authors. AS supervised the project.
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